A pioneering clinical trial is underway to test whether aging can be reversed and conditions leading to blindness treated by restoring lost cellular information. The trial, conducted by LifeBiosciences, a company co-founded by Harvard geneticist David Sinclair, aims to rejuvenate aging cells by re-establishing their original functions.
The study will enroll up to 18 participants, including 12 individuals with a form of glaucoma and six with non-arteritic anterior ischemic optic neuropathy (NAION). Both conditions result in vision loss due to the death of retinal cells, which the body cannot replace. Sinclair's hypothesis suggests these cells can be coaxed back from the brink by clearing cellular "noise" and re-establishing the original "signal."
This approach is based on Sinclair's "information theory of aging," which posits that cells age due to the cumulative effects of daily exposures. Building upon Shinya Yamanaka's discovery that four specific genes can reset cell age, Sinclair adapted the method using three genes. This modification aims to rejuvenate cells without reverting them to an embryonic state, allowing them to regain their original programming.
Sinclair believes this epigenetic age-restoring therapy could potentially reverse age-related diseases in various tissues, including the eye, liver, brain, and skin. Preliminary lab tests on animal models and human cells have indicated benefits across multiple tissue types. The eye was chosen as the initial focus for this therapy due to its isolation from the immune system, which could prevent immediate rejection of cells modified with Yamanaka factors. Additionally, the eye allows for relatively easy monitoring of vision changes and controlled activation or deactivation of the reprogramming process.
The longevity field is known for innovative concepts, but often lacks definitive proof of efficacy. Sinclair has faced criticism for making ambitious claims and launching ventures that have yet to yield substantial results. The scientific community is closely observing the outcomes of this trial, which Sinclair hopes will establish a new paradigm for cellular restoration, starting with the eye. "The mere fact that there is at least one person who has this in their bodies right now is something that will be seen as an important milestone," Sinclair stated. "Patients are now receiving a therapy that was designed to reverse the age of a tissue."